Table 2.
Characteristics of Participants by Age-at-study Entry and APOE ε4 status
| Age-at-entry < 80 years mean ± SD or n (%) |
Age-at-entry ≥ 80 years mean ± SD or n (%) |
|||||
|---|---|---|---|---|---|---|
| ε4 + (n=553) |
ε4 − (n=1526) |
total‡ (n=2343) |
ε4 + (n=149) |
ε4 − (n=527) |
total‡ (n=756) |
|
| Age-at-entry, years | 72.4 ± 3.8 | 72.7 ± 3.8 | 72.6 ± 3.8* | 84.0 ± 3.9 | 84.1 ± 3.5 | 84.2 ± 3.6 |
| Age at time of censoring | 78.8 ± 4.7† | 79.5 ± 4.6 | 79.2 ± 4.7* | 88.3 ± 4.7 | 88.8 ± 4.1 | 88.7 ± 4.2 |
| Duration of follow-up, year | 6.4 ± 3.2† | 6.8 ± 3.1 | 6.6 ± 3.2* | 4.3 ± 2.7 | 4.7 ± 2.9 | 4.5 ± 2.8 |
| Sex, male | 206 (37.3) † | 688 (45.1) | 994 (42.4)* | 56 (37.6) | 184 (34.9) | 262 (34.7) |
| Non-white | 62 (11.2) | 151 (9.9) | 256 (10.9)* | 8 (5.4) | 26 (4.9) | 46 (6.1) |
| Education, years | 14.3 ± 3.0 | 14.2 ± 3.0 | 14.3 ± 3.0* | 13.7 ± 3.0 | 13.3 ± 3.2 | 13.3 ± 3.2 |
| CASI score at entry | 93.7 ± 4.5 | 93.8 ± 4.5 | 93.6 ± 4.6* | 90.3 ± 5.9 | 91.0 ± 6.0 | 90.7 ± 5.9 |
| Comorbid conditions at entry | ||||||
| Cardiovascular disease | 113 (20.4) | 268 (17.6) | 433 (18.5)* | 37 (25.0) | 121 (23.0) | 175 (23.2) |
| Cerebrovascular disease | 60 (10.8) | 122 (8.0) | 215 (9.2)* | 20 (13.5) | 67 (12.7) | 98 (13.0) |
| Diabetes mellitus | 56 (10.1) | 168 (11.0) | 259 (11.1)* | 7 (4.7) | 36 (6.8) | 47 (6.2) |
| Hypertension | 207(37.4) | 574 (37.8) | 895 (38.3) | 55 (37.2) | 215 (41.0) | 307 (40.8) |
| Current cigarette smoking | 41 (7.4) | 101 (6.6) | 158 (6.7)* | 5 (3.4) | 17 (3.2) | 24 (3.2) |
| History of cigarette smoking | 294 (53.3) | 833 (54.6) | 1262 (53.9)* | 73 (49.0) | 244 (46.3) | 354 (46.8) |
| BMI | 27.7 ± 5.1 | 27.6 ± 4.9 | 27.7 ± 5.0* | 26.1 ± 4.2 | 26.1 ± 4.0 | 26.1 ± 4.1 |
| TC, mg/dl | 235.3 ± 35.6† | 229.0 ± 39.7 | 230.6 ± 38.8 | 237.1 ± 36.2† | 225.9 ± 37.1 | 229.3 ± 37.3 |
| HDL, mg/dl | 53.4 ± 14.7 | 54.1 ± 15.8 | 53.9 ± 15.7* | 55.3 ± 15.4 | 55.4 ± 15.1 | 55.8 ± 15.2 |
| Statin therapy | ||||||
| Frequency (%) | 140 (25.3) | 379 (24.8) | 596 (25.4)* | 26 (17.4) | 75 (14.2) | 115 (15.2) |
| Daily equivalent dose | 2.1 ± 1.3 | 2.2 ± 1.4 | 2.1 ± 2.0 | 2.0 ± 0.9 | 2.0 ± 1.0 | 2.0 ± 0.9 |
| Duration, years | 4.9 ± 3.3 | 4.8 ± 3.6 | 4.8 ± 3.5 | 4.8 ± 3.5 | 4.4 ± 3.3 | 4.6 ± 3.4 |
| Other LLA use | 76 (13.7) | 178 (11.7) | 292 (12.5)* | 9 (6.0) | 39 (7.4) | 52(6.9) |
| Dementia | 105 (19.0) † | 141 (9.2) | 281 (12.0)* | 50 (33.6) † | 128 (24.3) | 201 (26.6) |
| Probable AD | 65 (11.8) † | 72 (4.7) | 157 (6.7)* | 29 (19.5) † | 65 (12.3) | 106 (14.0) |
Information missing for CASI (n=1), education (n=3), Cardiovascular disease (n=4), Cerebrovascular disease (n=3), Diabetes mellitus (n=2), Hypertension (n=12) and BMI (n=49).
*
p< 0.05 for difference between age groups (age < 80 vs age ≥ 80 years) in either t-test or χ2 test.
†
p <0.05 for difference between those with and without ε4 allele.
‡
includes participants with missing APOE.
SD: standard deviation; CASI: Cognitive Abilities Screening Instrument (score range 0 – 100); BMI: body mass index; TC: total cholesterol; HDL: high density lipoprotein; LLA: other lipid lowering agent; and AD: Alzheimer disease.